ACAD vs MEDP
ACADIA Pharmaceuticals Inc. vs Medpace — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
| Metric | ACAD | MEDP |
|---|
| AI Score |
67
|
64
|
| Price |
$29.46
|
$596.78
|
| P/E Ratio |
13.07×
|
34.82×
|
| ROE |
31.9%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
28.8%
|
| Debt / Equity |
0.06×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
72.1
|
| Beta |
0.845
|
1.151
|
| Expected Upside |
—
|
+3.0%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus MEDP.
ACAD leads by 3 points.
ACAD scores 67/100 (Buy) versus MEDP at 64/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical